Payment overview · 2025
General Payments
$1,947.33
75 reported records · 20 companies
Healthcare provider profile · identity verified
Richard Mark Shaw, MD
Allopathic & Osteopathic Physicians|Family Medicine · SIMI VALLEY, CA · NPI 1376537753
Verified facts
What the public records show
CMS Open Payments records show Richard Mark Shaw, MD received $1,947.33 in general payments during 2025 across 75 reported records.
Novo Nordisk Inc accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $423.47 | 21.8% | 18 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $416.63 | 21.4% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $288.50 | 14.8% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $140.37 | 7.2% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $114.10 | 5.9% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $105.76 | 5.4% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $94.85 | 4.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.32 | 2.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.64 | 2.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $38.56 | 2.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.77 | 1.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $33.98 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $25.53 | 1.3% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $24.52 | 1.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.41 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.34 | 1.2% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $18.03 | 0.9% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $16.54 | 0.8% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $15.87 | 0.8% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.14 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,947.33 | 75 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $345.45 | 14 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $225.24 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $181.83 | 8 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $179.00 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $176.24 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $140.37 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $105.76 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $94.85 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $83.69 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.26 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.26 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $53.96 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.32 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.32 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.06 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.64 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.56 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.77 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $34.77 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.77 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $33.98 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.94 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 69 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 33 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 566 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 320 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 88 |
| Losartan Potassium | Losartan Potassium | 231 | 70 |
| Lisinopril | Lisinopril | 219 | 64 |
| Metformin Hcl | Metformin Hcl | 217 | 64 |
| Gabapentin | Gabapentin | 216 | 67 |
| Pravastatin Sodium | Pravastatin Sodium | 184 | 52 |
| Omeprazole | Omeprazole | 150 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 43 |
| Alendronate Sodium | Alendronate Sodium | 146 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 145 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 42 |
| Allopurinol | Allopurinol | 127 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 37 |
| Trazodone Hcl | Trazodone Hcl | 120 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 34 |
| Simvastatin | Simvastatin | 117 | 33 |
| Carvedilol | Carvedilol | 112 | 35 |
| Furosemide | Furosemide | 95 | 31 |
| Famotidine | Famotidine | 90 | 33 |
| Ezetimibe | Ezetimibe | 79 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 78 | 36 |
| Doxazosin Mesylate | Doxazosin Mesylate | 77 | 25 |
| Montelukast Sodium | Montelukast Sodium | 75 | 23 |
| Jardiance | Empagliflozin | 69 | 18 |
| Potassium Chloride | Potassium Chloride | 69 | 20 |
| Baclofen | Baclofen | 63 | 24 |
| Tramadol Hcl | Tramadol Hcl | 62 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 19 |
| Alprazolam | Alprazolam | 54 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | suppressed |
| Prednisone | Prednisone | 45 | 36 |
| Atenolol | Atenolol | 44 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | 12 |
| Eliquis | Apixaban | 42 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 15 |
| Valsartan | Valsartan | 39 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Finasteride | Finasteride | 36 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | 13 |
| Clonazepam | Clonazepam | 34 | 15 |
| Ozempic | Semaglutide | 34 | suppressed |
| Rybelsus | Semaglutide | 33 | 11 |
| Spironolactone | Spironolactone | 33 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | suppressed |
| Glimepiride | Glimepiride | 31 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | 13 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | 11 |
| Azelastine Hcl | Azelastine Hcl | 27 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | 11 |
| Sucralfate | Sucralfate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Indapamide | Indapamide | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Procto-Med Hc | Hydrocortisone | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Prolia | Denosumab | 16 | 11 |
| Telmisartan | Telmisartan | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,947.33 · 75 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, CONTRAVE, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, ImmunoCAP, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LOREEV XR, LifeVest, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error